Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.

Journal of translational medicine - 31 Oct 2023

Laurent Pierre-Antoine, Milic Marina, Quevrin Clément, Meziani Lydia, Liu Winchygn, Morel Daphné, Signolle Nicolas, Clémenson Céline, Levy Antonin, Mondini Michele, Deutsch Eric

Abstract excerpt

BACKGROUND: KRAS activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati Therapeutics) showed encouraging clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37907934
DOI: 10.1186/s12967-023-04619-0
PMCID: PMC10619254

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.PMID 37907934Read ↗

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partnerSemantic proximity Read ↗

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsSemantic proximity Read ↗

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and Carbon ions irradiationSemantic proximity Read ↗

Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer.Semantic proximity Read ↗

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read ↗

Inhibition of ULK1/2 and KRAS <sup>G12C</sup> controls tumor growth in preclinical models of lung cancerSemantic proximity Read ↗

Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Semantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation.Semantic proximity Read ↗

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.